Zaocys type II collagen regulates mesenteric lymph node Treg/Th17 cell balance in mice with collagen-induced arthritis
10.3969/j.issn.1673-4254.2014.05.05
- VernacularTitle:乌梢蛇Ⅱ型胶原蛋白调控胶原诱导性关节炎小鼠肠系膜淋巴结Treg/Th17平衡
- Author:
Hao WANG
1
;
Zhitao FENG
;
Junqing ZHU
;
Juan LI
Author Information
1. 南方医科大学南方医院中医科
- Keywords:
type II collagen;
rheumatoid arthritis;
collagen-induced arthritis;
Treg/Th17;
oral tolerance
- From:
Journal of Southern Medical University
2014;(5):622-626
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of oral administration of Zaocys type II collagen (ZCII) on the percentages of Treg/Th17 cells in mesenteric lymph node lymphocytes (MLNLs) in mice with collagen-induced arthritis (CIA). Methods CIA was induced in male C57BL/6 mice by immunization with chicken type II collagen. Three weeks later, ZCII, purified by pepsin digestion, was orally administered in the mice for 7 consecutive days (daily dose of 10, 20, or 40 μg/kg). The severity of arthritis in each limb was evaluated using a macroscopic scoring system, and histopathological changes of the joint were observed microscopically with HE staining. The percentages of Treg and Th17 cells in MLNLs was detected by flow cytometry, and the levels of transforming growth factor-β(TGF-β) and interleukin-17 (IL-17) in the supernatant of MLNLs were measured by enzyme-linked immunosorbent assay. Results Compared with normal control mice, the mice with CIA had significantly higher scores for arthritis and histopathological changes, with also significantly increased percentages of Treg and Th17 cells in MLNLs and elevated levels of TGF-β and IL-17 in MLNL supernatant (P<0.05). In ZCII peptide-treated mice, the scores for arthritis and histopathological changes were significantly lower than those in CIA model group (P<0.05), and Treg cell percentage in MLNLs was up-regulated while Th17 cell percentage lowered;the level of TGF-βwas increased but IL-17 was decreased significantly (P<0.05). Conclusion Oral administration of ZCII improves CIA in mice by regulating the percentages of Treg/Th17 cells and the cytokine levels in MLNLs, suggesting the value of ZCII as a promising candidate agent for treatment of rheumatoid arthritis.
